Baidu
map

Nephrology :慢性肾病:甲状旁腺激素治疗的目标及对甲状旁腺功能亢进症的管理

2017-08-04 门鹏 环球医学资讯

矿物质骨疾病常见于慢性肾病中,主要受继发性甲状旁腺功能亢进症(HPT)驱动。其诊断和治疗是复杂的,但对甲状旁腺激素(PTH)的测量和制定目标是几十年来治疗的重点。2017年5月,发表在《Nephrology (Carlton)》的一项由澳大利亚科学家进行的研究,考察了慢性肾病(CKD)患者进行甲状旁腺激素(PTH)治疗的目标及对HPT的管理。

矿物质骨疾病常见于慢性肾病中,主要受继发性甲状旁腺功能亢进症(HPT)驱动。其诊断和治疗是复杂的,但对甲状旁腺激素(PTH)的测量和制定目标是几十年来治疗的重点。2017年5月,发表在《Nephrology (Carlton)》的一项由澳大利亚科学家进行的研究,考察了慢性肾病(CKD)患者进行甲状旁腺激素(PTH)治疗的目标及对HPT的管理

对CKD 3-5D期患者的PTH治疗的适当目标有争议,尽管以这些为目标的方法可能实现。继发性HPT与骨痛和瘙痒等症状有关,另外还有临床上较少出现的如骨骼脆弱及血管和软组织钙化等问题,这些可能导致不良的硬终点,尤其是骨折和死亡。管理增加PTH公认的疗法包括维生素D衍生物、有无拟钙剂(可及),此外还有通过饮食、粘合剂和透析对血清中矿物质浓度的管理。尽管有这些干预措施,许多患者最终还是会发展为重度HPT的难治性代谢异常。在澳大利亚,以症状缓解、骨折复位和降低血管风险为目标,重度HPT的治疗决策以前围绕在是否做甲状旁腺切除术或使用拟钙剂联合骨化三醇(或它的衍生物)。在2015年,澳大利亚决定删除《药品福利计划》(Pharmaceutical Benefits Scheme)中对拟钙剂西那卡塞的报销项目,这意味着甲状旁腺切除术已经成为唯一可能对多数重度HPT患者有利的治疗方法。尽管CKD患者的治疗改善很明显,但迫切需要基础科学和大型国际试验来提供管理HPT更好的方法。

专家点评:严重甲旁亢患者,有手术指征一般均优先手术治疗。

原始出处:
Hawley CM, Holt SG.Parathyroid hormone targets in chronic kidney disease and managing severe hyperparathyroidism.Nephrology (Carlton). 2017 Mar;22 Suppl 2:47-50. doi: 10.1111/nep.13029.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1307376, encodeId=d436130e37672, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379541, encodeId=11be13e9541c9, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452451, encodeId=d34514524510d, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229979, encodeId=284a2299e940, content=看过了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Aug 04 14:51:08 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229964, encodeId=d757229964de, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Aug 04 14:25:11 CST 2017, time=2017-08-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1307376, encodeId=d436130e37672, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379541, encodeId=11be13e9541c9, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452451, encodeId=d34514524510d, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229979, encodeId=284a2299e940, content=看过了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Aug 04 14:51:08 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229964, encodeId=d757229964de, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Aug 04 14:25:11 CST 2017, time=2017-08-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1307376, encodeId=d436130e37672, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379541, encodeId=11be13e9541c9, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452451, encodeId=d34514524510d, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229979, encodeId=284a2299e940, content=看过了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Aug 04 14:51:08 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229964, encodeId=d757229964de, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Aug 04 14:25:11 CST 2017, time=2017-08-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1307376, encodeId=d436130e37672, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379541, encodeId=11be13e9541c9, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452451, encodeId=d34514524510d, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229979, encodeId=284a2299e940, content=看过了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Aug 04 14:51:08 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229964, encodeId=d757229964de, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Aug 04 14:25:11 CST 2017, time=2017-08-04, status=1, ipAttribution=)]
    2017-08-04 明天会更好!

    看过了。。。。。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1307376, encodeId=d436130e37672, content=<a href='/topic/show?id=b1d766836e4' target=_blank style='color:#2F92EE;'>#激素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66836, encryptionId=b1d766836e4, topicName=激素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379541, encodeId=11be13e9541c9, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452451, encodeId=d34514524510d, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Aug 06 02:01:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229979, encodeId=284a2299e940, content=看过了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Aug 04 14:51:08 CST 2017, time=2017-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=229964, encodeId=d757229964de, content=非常好的文章,学习了,很受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Fri Aug 04 14:25:11 CST 2017, time=2017-08-04, status=1, ipAttribution=)]
    2017-08-04 天涯183

    非常好的文章,学习了,很受益

    0

相关资讯

Heart:房颤合并慢性肾病患者如何抗凝有学问

2017年6月,发表在《Heart》的一项由美国科学家进行的研究考察了房颤(AF)合并慢性肾病(CKD)患者中,华法林的使用和抗凝控制情况。

慢性肾病变得如此普遍,这是为什么?

三千万美国成年人患有慢性肾脏疾病,但有许多人不了解它。

NEJM:健康人群中单肾小球滤过率研究

健康的肾供体,单肾肾小球滤过率与年龄、性别和身高不相关,高单肾肾小球滤过率是慢性肾脏疾病和某些肾活检风险结果的体现。

宋庆龄基金会“橙心关爱” -- “橙就梦想”公益项目正式启动

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li

Circulation:慢性肾病与心脏疾病密切相关,增加了心血管疾病患者的不良预后风险!

慢性肾病(CKD)被认为是全球公共卫生问题。最新的国际临床指南强调肾小球滤过率(GFR)和蛋白尿。CKD与心脏疾病密切相关,增加心血管疾病(CVD)患者的不良预后风险。事实上,大量的研究已经研究了CKD预后与心血管病患者的关系,但大多数研究都集中在肾功能上,对蛋白尿研究的数据有限。

2016共识声明:患有糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整

糖尿病患者肾功能衰退对于临床医生来讲具有挑战性,包括并发症的管理例如,高血压高脂血症,心血管疾病,贫血等。本文主要针对糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整提出指导建议。

Baidu
map
Baidu
map
Baidu
map